Design Therapeutics Inc
$ 10.09
-2.70%
05 Mar - close price
- Market Cap 590,714,000 USD
- Current Price $ 10.09
- High / Low $ 10.37 / 9.87
- Stock P/E N/A
- Book Value 3.51
- EPS -1.19
- Next Earning Report 2026-03-09
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.20 %
- ROE -0.30 %
- 52 Week High 11.14
- 52 Week Low 2.60
About
Design Therapeutics, Inc. develops therapies for the treatment of degenerative disorders caused by nucleotide repeat expansions. The company is headquartered in Carlsbad, California.
Analyst Target Price
$14.40
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-05 | 2025-08-07 | 2025-05-06 | 2025-03-17 | 2024-11-11 | 2024-08-05 | 2024-05-08 | 2024-03-19 | 2023-11-13 | 2023-08-14 | 2023-05-09 | 2023-03-14 |
| Reported EPS | -0.3 | -0.34 | -0.31 | -0.24 | -0.23 | -0.21 | -0.2 | -0.21 | -0.28 | -0.36 | -0.35 | -0.31 |
| Estimated EPS | -0.3367 | -0.2967 | -0.28 | -0.2667 | -0.24 | -0.23 | -0.26 | -0.31 | -0.41 | -0.4 | -0.36 | -0.34 |
| Surprise | 0.0367 | -0.0433 | -0.03 | 0.0267 | 0.01 | 0.02 | 0.06 | 0.1 | 0.13 | 0.04 | 0.01 | 0.03 |
| Surprise Percentage | 10.8999% | -14.5939% | -10.7143% | 10.0112% | 4.1667% | 8.6957% | 23.0769% | 32.2581% | 31.7073% | 10% | 2.7778% | 8.8235% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-09 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.37 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: DSGN
2026-03-02 02:51:20
This page provides the latest news and market updates for Design Therapeutics, Inc. (DSGN), a clinical-stage biotechnology company focused on degenerative genetic diseases. It highlights the company's GeneTAC pipeline progress, financial results, and corporate events. Recent updates include details on their IPO, Q1 2021 financial results, and clinical trial plans for Friedreich ataxia.
2026-03-01 18:51:48
DelveInsight's report on the Fuchs Dystrophy pipeline highlights over 5 key companies developing 5+ treatment therapies for the condition, including Kowa Pharma, Trefoil Therapeutics, Design Therapeutics, Emmecell, and Santen. The report provides a comprehensive assessment of these pipeline products, covering their mechanism of action, clinical study status, and developmental activities. It also discusses market drivers such as the aging population and opportunities, as well as obstacles like a lack of awareness and universal treatment guidelines.
2026-02-28 18:51:48
This page provides a compilation of recent news and events related to Design Therapeutics (DSGN) stock, including its price performance and significant company announcements. The news highlights include stock movements, participation in investor conferences, clinical data presentations, and financial results. Currently, there are no upcoming events, monitor news, or earnings analysis specifically for DSGN listed on this page.
2026-02-28 16:52:07
This article provides an overview of the Fuchs Dystrophy treatment pipeline in 2026, highlighting key companies like Kowa Pharma, Trefoil Therapeutics, Design Therapeutics, Emmecell, and Santen, and the therapies they are developing. DelveInsight's report details clinical trial statuses, mechanisms of action, and routes of administration for these emerging treatments. The article also mentions Design Therapeutics' favorable Phase I trial results for DT-168, a GeneTAC small molecule, which shows promise for Fuchs endothelial corneal dystrophy (FECD).
2026-02-27 23:51:31
This DelveInsight report, "Fuchs Dystrophy Pipeline Insight, 2026," provides a comprehensive overview of the global pipeline for Fuchs Dystrophy treatments, detailing over five key companies and therapies in various stages of clinical development. It highlights the mechanism of action, route of administration, and clinical trial status of emerging drugs, including a promising Phase I trial from Design Therapeutics. The report also addresses market dynamics, such as increasing demand due to the aging population, and challenges like a lack of awareness about the disease.
2026-02-26 15:53:08
Design Therapeutics (NASDAQ: DSGN) outlined its GeneTAC pipeline progress at an Oppenheimer conference, including upcoming data for Friedreich's ataxia (FA) in late 2026 and plans to begin dosing DM1 patients in the first half of 2026. The company's small-molecule approach aims to modulate gene expression for single-gene disorders, with preclinical data showing promising results for DT-216 in FA, DT-818 in DM1, and DT-168 eye drops in Fuchs' endothelial corneal dystrophy (FECD). Design Therapeutics reported $206 million in cash at the end of Q3, providing runway for its clinical programs toward proof-of-concept.
